| Document |
Document Title |
|
WO/2022/187010A1 |
Disclosed herein is a method including decoupling one or more polymers containing the residue of a propiolactone, an epoxide, or both from a metal centered compound in a composition to form a Lewis acid containing one or more polar ligan...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/038365A9 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
|
|
WO/2022/133027A1 |
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment o...
|
|
WO/2022/130352A1 |
Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/120353A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/112351A1 |
The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of sai...
|
|
WO/2022/090723A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA1, RA2, R1 to R5, L and RB are as defined herein.
|
|
WO/2022/091045A2 |
|
|
WO/2022/063071A1 |
Provided in the present invention are a novel inhibitor simultaneously targeting PTL and NPC1L1 and the use thereof. Namely, provided are a compound having a structure as represented by formula (I) and the use thereof in the preparation ...
|
|
WO/2022/022448A1 |
The present invention belongs to the pharmaceutical field. Specifically, the present invention relates to a neuraminidase inhibitor compound as represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, or a ...
|
|
WO/2022/018594A1 |
This invention relates novel intermediates used for the synthesis of substituted 3,4-dihydroisoquinolinone compounds which are EZH2 inhibitors and the synthesis of said intermediates.
|
|
WO/2021/252607A1 |
Functionalized beta-propiolactone in which one or more of the carbons or the ring structure are substituted with either hydrogen or a hydrocarbyl moiety which may contain heteroatoms and substituents.
|
|
WO/2021/243415A1 |
Provided herein is dendrimer-targeting agent conjugate comprising: (a) a dendrimer comprising i) a core unit (C); and ii) building units (BU), wherein the dendrimer has from two to six generations of building units; and wherein the core ...
|
|
WO/2021/226433A1 |
Provided is a method of producing an anhydride of an organic mono-acid comprising contacting an organic mono-acid and a thermally regenerable anhydride to produce the anhydride of the organic mono-acid, and either a diacid of the regener...
|
|
WO/2021/226276A2 |
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...
|
|
WO/2021/204175A1 |
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...
|
|
WO/2021/197058A1 |
The present invention provides a method for synthesizing an oxetane compound by a microreactor. The synthesis method comprises: introducing trimethylolpropane and carbonate into the microreactor in the presence of an alkaline catalyst, a...
|
|
WO/2021/197057A1 |
The present invention provides a synthesis method for synthesizing an oxetane derivative by a microreactor. The synthesis method comprises: delivering 3-ethyl-3-hydroxymethyl oxetane, a raw material Ha, a catalyst and an alkali into a mi...
|
|
WO/2021/194298A1 |
The present invention relates to nanoparticles comprising drug dimers, and a use thereof. The nanoparticles comprising drug dimers, of the present invention, can increase drug content and improve the drug dispersibility. In addition, the...
|
|
WO/2021/170464A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R9 represent groups such as hydrogen, halogen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a divalent ...
|
|
WO/2021/163811A1 |
Provided herein are compositions including polymeric binder or a salt thereof, high molecular weight polymer, pharmaceutically active agent and a low molecular weight cross-linking agent, methods for using the compositions to coat a subs...
|
|
WO/2021/161887A1 |
[Problem] To provide a novel compound which has high absorption selectivity for the long-wavelength ultraviolet to near ultraviolet region close to a wavelength of 400 nm, exhibits high weathering resistance, and has a merocyanine skelet...
|
|
WO/2021/159015A1 |
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...
|
|
WO/2021/118906A1 |
A process and intermediate for the preparation of a compound of formula (I), or salt thereof.
|
|
WO/2021/113806A1 |
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating dis...
|
|
WO/2021/110004A1 |
A weak acidic paclitaxel derivative active drug-loading liposome, a preparation method therefor and use thereof. The present invention relates to a weak acidic derivative of paclitaxel. The weak acidic derivative uses paclitaxel as a raw...
|
|
WO/2021/109944A1 |
The present invention relates to a weak alkaline carbazitaxel derivative and a formulation thereof, and specifically relates to the synthesis of the weak alkaline carbazitaxel derivative, a liposome formulation comprising the derivative,...
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102567A1 |
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors....
|
|
WO/2021/097650A1 |
The invention belongs to the technical field of medicines, and particularly relates to a cocrystal of orlistat and an amino acid, and a pharmaceutical composition comprising the same. The cocrystal formed by orlistat and L-proline, L-leu...
|
|
WO/2021/086454A1 |
A process for introducing a substituted olefin epoxide stream comprising a substituted olefin epoxide and a carbon monoxide stream comprising carbon monoxide into a carbonylation reactor; and carbonylating at least a portion of the subst...
|
|
WO/2021/069927A1 |
The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk o...
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/029362A1 |
The present disclosure provides a composition for improving the conductivity of a conductive component or conductive material, the composition comprising the compound represented by formula (4). The present disclosure further provides a ...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/021384A1 |
A process for oxidizing iso-butane with oxygen to produce t-butyl hydroperoxide and t-butyl alcohol; dehydrating at least a portion of the t-butyl alcohol to produce di-tert-butyl ether and isobutylene; epoxidizing at least a portion of ...
|
|
WO/2021/009026A1 |
Compounds of formula (I): (Formula (I)) Formula (I) encompasses e.g. tetraline, chromane, isochromane, 6,7,8,9-tetrahydrobenzo[7]annulene, 1H-isobenzofurane and indane derivatives. The compounds of formula (I) are useful as a pesticides,...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/009568A1 |
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2020/253839A1 |
The present invention relates to a compound represented by formula (I), wherein variables n, m, z, p, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the description. The compound represented by formula (I) not only has, after photoc...
|
|
WO/2020/249507A1 |
An anhydrous, crystalline form of Cabazitaxel [Form (H-1)] is herein disclosed. Form H-1 shows a13C SS-NMR spectrum featuring one single polymorph and showing the same advantages as known form H with respect to known Form D in terms of s...
|
|
WO/2020/249473A1 |
The invention relates to a process for the carbonylation of epoxides in the presence of catalyst systems, wherein the carbonylation takes place in the presence of carbon monoxide, and wherein the catalyst system contains a molybdenum-bas...
|
|
WO/2020/239980A1 |
The present invention relates to an arthropod controlling composition comprising a compound according to formula (I), methods and uses to control arthropods as well as arthropod controlling articles comprising the same.
|
|
WO/2020/243754A1 |
Provided herein is a method of forming a beta-lactone from a carboxylic acid having a beta-carbon with a hydrogen atom disposed thereon. The method comprises contacting a carboxylic acid of formula (1) as described herein with an effecti...
|
|
WO/2020/223813A1 |
There is described herein a nanoparticle comprising an outer shell comprising a porphyrin salt, an expanded porphyrin salt or an analog of porphyrin salt, around an inner oil core.
|
|
WO/2020/222010A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein R A, R B, R C and R D are as defined herein.
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
